Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
Daiichi Sankyo
Express Scripts
QuintilesIMS
Argus Health
Deloitte

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,858,996

« Back to Dashboard

Which drugs does patent 8,858,996 protect, and when does it expire?

Patent 8,858,996 protects VIMOVO and is included in one NDA.

This patent has thirty-five patent family members in twenty-two countries.
Summary for Patent: 8,858,996
Title:Pharmaceutical compositions for the coordinated delivery of NSAIDS
Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
Inventor(s): Plachetka; John R. (Chapel Hill, NC)
Assignee: Pozen Inc. (Chapel Hill, NC)
Application Number:14/244,471
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

Drugs Protected by US Patent 8,858,996

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 AB RX Yes No ➤ Sign Up ➤ Sign Up Y RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,858,996

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,557,285 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
8,852,636 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
8,865,190 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
6,926,907 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
McKesson
UBS
Colorcon
Cerilliant
Fish and Richardson
Covington
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.